$13.6 Million Accutane Verdict Reversed; New Trial Ordered

ATLANTIC CITY, N.J. - A New Jersey appellate court has reversed a $13.6 million Accutane judgment and ordered a new trial, ruling that the trial court erred in preventing Hoffman-La Roche Inc. from presenting data concerning the rate of inflammatory bowel disease in the general population as compared to the rate of IBD in Accutane users. Kendall v. Hoffman-La Roche Inc., No. ATL-L-8213-05-MT (N.J. Super., Atlantic Cty.).

The New Jersey Superior Court, Appellate Division, ruled that the drug maker was unfairly impeded at trial from presenting numerical proofs that could have led the jury to reach a different verdict.

Kamie …